Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment-Reference-Cited by-同舟云学术

Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment

Published:2021-01-15 Issue:7 Volume:77 Page:989-998
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Wu Wanhong,Ke Meng,Ye Lingling,Lin Cuihong^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00228-020-03072-y.pdf

Reference20 articles.

1. Al Jalali V, Zeitlinger M (2018) Clinical pharmacokinetics and pharmacodynamics of telavancin compared with the other glycopeptides. Clin Pharmacokinet 57(7):797–816. https://doi.org/10.1007/s40262-017-0623-4

2. Cumberland Pharmaceuticals Inc (2020) VIBATIV® (telavancin) for injection, for intravenous use [prescribing information]. Cumberland Pharmaceuticals Inc., Nashville, TN 37203

3. Adamantia L, Antoni T (2016) Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia. Expert Opin Drug Metab Toxicol 12(7):803–812. https://doi.org/10.1080/17425255.2016.1187599

4. Shaw JP, Cheong J, Goldberg MR, Kitt MM (2010) Mass balance and pharmacokinetics of [14C] telavancin following intravenous administration to healthy male volunteers. Antimicrob Agents Chemother 54(8):3365–3371. https://doi.org/10.1128/aac.01750-09

5. Stryjewski M, Chu V, O'Riordan W, Warren B, Dunbar L, Young D, Vallée M, Fowler V, Morganroth J, Barriere S, Kitt M, Corey G (2006) Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 50(3):862–867. https://doi.org/10.1128/aac.50.3.862-867.2006

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically based pharmacokinetic modeling in obesity: applications and challenges;Expert Opinion on Drug Metabolism & Toxicology;2024-08-12

2. In vivo anti-inflammatory activity of BACCHARIN from BRAZILIAN green PROPOLIS;Fitoterapia;2024-06

3. Chronic kidney disease and physiologically based pharmacokinetic modeling: a critical review of existing models;Expert Opinion on Drug Metabolism & Toxicology;2024-01-31

4. Pharmacokinetics and safety of a single dose of telavancin in pediatric subjects 2–17 years of age;Antimicrobial Agents and Chemotherapy;2023-11-15

5. Comprehensive guidance for antibiotic dosing in obese adults: 2022 update;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2023-02-18